Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Cindy Delbrook"'
Autor:
Alan S. Wayne, Melinda S. Merchant, Nalini Jayaprakash, Kelly Richards, Diane E. Cole, Nirali N. Shah, Donna Bernstein, Cindy Delbrook, Brigitte C. Widemann
Publikováno v:
Pediatric Blood & Cancer. 63:997-1005
Background Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin/cholesterol liposomes. Clinical trials in adults have demonstrated safety, tolerability, and activity, leading
Disease Detection Methodologies in Acute Lymphoblastic Leukemia (ALL): Opportunities for Improvement
Autor:
Amita Kulshreshtha, Constance M. Yuan, Daniel W. Lee, Maryalice Stetler-Stevenson, Terry J. Fry, Dalia Salem, Alina Dulau-Florea, Cindy Delbrook, Bonnie Yates, Joanne Derdak, Gaurav K. Gupta, Crystal L. Mackall, Nirali N. Shah, Alan S. Wayne, Haneen Shalabi
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S108-S109
Background Minimal residual disease (MRD) is highly prognostic for outcomes in ALL, particularly prior to HCT. New methods for MRD determination in bone marrow (BM) increase the sensitivity of disease detection but remain dependent on the quality of
Autor:
Steven A. Rosenberg, Constance M. Yuan, Marianna Sabatino, Terry J. Fry, Ling Zhang, Hua Zhang, Crystal L. Mackall, Rimas J. Orentas, Alan S. Wayne, Steven A. Feldman, Maryalice Stetler-Stevenson, James N. Kochenderfer, Dave Stroncek, Cindy Delbrook, Nick Tschernia, Nirali N. Shah, Seth M. Steinberg, Daniel W. Lee, Yongzhi K Cui
Publikováno v:
Lancet (London, England). 385(9967)
Summary Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of cons
Autor:
David F. Stroncek, Daniel W. Lee, Bonnie Yates, Ling Zhang, Constance M. Yuan, Hua Zhang, Maryalice Stetler-Stevenson, Steven A. Rosenberg, Cindy Delbrook, Terry J. Fry, Nirali N. Shah, Crystal L. Mackall, James N. Kochenderfer
Publikováno v:
Blood. 128:218-218
Relapsed pre-B acute lymphoblastic leukemia (ALL) portends a poor prognosis even with hematopoietic stem cell transplantation (HSCT). CD19 chimeric antigen receptor (CAR) T cells have shown promise in early studies although morbidity related tohigh g
Autor:
Kazusa Ishii, Haneen Shalabi, Bonnie Yates, Terry J. Fry, Nirali N. Shah, Crystal L. Mackall, Cindy Delbrook
Publikováno v:
Blood. 128:3358-3358
Background: Cytokine release syndrome (CRS) in the setting of CAR T cell therapy manifests as a wide constellation of symptoms with multi-organ involvement. CRS can vary from a mild, self-limited course to a life-threatening systemic inflammatory res
Autor:
Cindy Delbrook, Constance M. Yuan, David F. Stroncek, Nirali N. Shah, Terry J. Fry, Crystal L. Mackall, Ling Zhang, Maryalice Stetler-Stevenson, Daniel W. Lee, Bonnie Yates
Publikováno v:
Blood. 126:1324-1324
Background: Adoptive cellular therapy with genetically modified T-cells using viral-based vectors to express chimeric antigen receptors targeting the CD19 molecule have demonstrated dramatic clinical responses in patients ALL. However, not all patien
Autor:
Ling Zhang, Maryalice Stetler-Stevenson, David F. Stroncek, Daniel W. Lee, Cindy Delbrook, Terry J. Fry, Marianna Sabatino, Alan S. Wayne, Steven R. Feldman, Yongzhi Cui, Nirali N. Shah, Crystal L. Mackall, Constance M. Yuan, Nick Tschernia, Hua Zhang, James N. Kochenderfer, Steven A. Rosenberg, Bonnie Yates
Publikováno v:
Blood. 124:381-381
Relapsed or refractory acute lymphoblastic leukemia (ALL) remains a difficult therapeutic challenge. We developed a platform where T cells are collected, transduced via retrovirus with a chimeric antigen receptor (CAR) targeting CD19 and incorporatin
Autor:
Steven A. Rosenberg, James N. Kochenderfer, David F. Stroncek, Alan S. Wayne, Daniel W. Lee, Crystal L. Mackall, Nirali N. Shah, Maryalice Stetler-Stevenson, Cindy Delbrook, Marianna Sabatino, Kelly Richards
Publikováno v:
Blood. 122:68-68
Survival after relapsed and refractory pediatric pre-B ALL and non-Hodgkin lymphoma (NHL) is poor despite intensive chemotherapy and HSCT. CAR T cells combine the specificity and MHC independence of antibodies with the cytotoxic capacity of T cells.
Autor:
Marianna Sabatino, Alan S. Wayne, Steven A. Rosenberg, Cindy Delbrook, Daniel W. Lee, James N. Kochenderfer, Crystal L. Mackall, David F. Stroncek, Kelly Richards, Maryalice Stetler-Stevenson, Nirali N. Shah
Publikováno v:
Cancer Research. 73:LB-138
Introduction: Despite aggressive therapies such as HSCT, survival in relapsed and refractory pediatric ALL and NHL is poor. CAR modified T cells targeting CD19 have been effective in adult B-cell malignancies. These studies have employed T cells eith
Autor:
Marianna Sabatino, David F. Stroncek, Cindy Delbrook, Alan S. Wayne, Daniel W. Lee, Steven A. Rosenberg, Crystal L. Mackall, James N. Kochenderfer, Maryalice Stetler-Stevenson, Kelly Richards, Barbara Tumaini
Publikováno v:
Blood. 120:2609-2609
Abstract 2609 Children with relapsed or chemotherapy-refractory ALL have a poor prognosis despite the use of aggressive therapies such as HSCT. Chimeric antigen receptor modified T cells targeting the B-cell antigen CD19 have been reported to be effe